Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cell therapy for cardiac repair through mobilization of hematopoietic stem cells and endothelial progenitors in chronic ischemic cardiomyopathy
2004-004545-18Phase 2Completed
- Sponsor
- Centre Hospitalier Universitaire de Liège
- Start
- Dec 2005
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of filgrastim and epoetin beta in ischaemic cardiomyopathy (ICM) (3 arms), sponsored by Centre Hospitalier Universitaire de Liège. Primary endpoints: Mobilized stem and progenitor cell counts in peripheral blood and Bone marrow stem and progenitor cell content. Started Dec 2005; status: completed.
02
Drugs
filgrastimepoetin beta
03
Conditions
ischaemic cardiomyopathy (ICM)
Beyond the preview
Go deeper on 2004-004545-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004545-18.